Drug intelligence / Profile preview

betamethasone + etanercept

Development stage: Unknown
Lead developer: Amgen
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Topical

Overview

A combination therapy consisting of betamethasone, a corticosteroid with anti-inflammatory properties, and etanercept, a dimeric fusion protein that binds to tumor necrosis factor alpha (TNF-alpha). This combination is used primarily for the treatment of plaque psoriasis, where etanercept provides systemic immunomodulation while betamethasone (often formulated with calcipotriene) offers topical anti-inflammatory effects. The combination has been shown to be particularly effective in maintaining response during etanercept maintenance therapy.

Targets

TNFA (Tumor necrosis factor alpha (soluble))GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on betamethasone + etanercept.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on betamethasone + etanercept.

Explore the full profile